MicroDose Therapeutx will receive additional payments of up to USD125m upon achievement of regulatory and development milestones, plus sales-based milestones and tiered royalty payments upon commercialisation of MDT-637 and an earlier stage Asthma/COPD medicine.
A drug delivery company, MicroDose Therapeutx is focused on inhalation technologies and products for lung diseases and infections with the potential to dramatically improve efficacy and patient compliance.
Upon closing, Teva will expand its respiratory pipeline of MicroDose's technologies and products, including its multi-dose dry powder nebulizer device. MicroDose's current pipeline is anchored by MDT-637 for respiratory syncytial virus (RSV) - an inhaled, low dose, small molecule, fusion inhibitor which prevents viral replication, delivered via MicroDose's technology.
Perrigo to acquire United States rights for Entocort from AstraZeneca
US FDA approves Boehringer Ingelheim's Pradaxa
Phase II clinical trial for potential treatment of androgenetic alopecia completed by Samumed
Life Sciences Partners collaborates on immuno-oncology with Bristol-Myers Squibb
Arsanis initiates first cohort in Phase one clinical trial of ASN100
Impax introduces generic Avodart (Dutasteride) Capsules, 0.5 mg
Mylan unveils generic FazaClo orally disintegrating tablets for treating schizophrenia